DOWNLOAD
1 min read
Putting patients at the center of a new biopharma business model

The pharmaceutical industry is suffering. Expiring patents, increasing demands from regulators and decreasing healthcare budgets are putting companies under pressure, and the industry has to walk a narrow tightrope between keeping profitability up and quickly developing attractive medications. As patients are increasingly well informed, organized and powerful, a novel approach that some companies are looking into is patient-centrism. This means integrating patient inputs in each stage of the value chain, from drug development through commercialization to lifecycle management. We carried out 50 in-depth interviews with industry experts to find out how this new model can hold the future for the bio pharma business.


The pharmaceutical industry is suffering. Expiring patents, increasing demands from regulators and decreasing healthcare budgets are putting companies under pressure, and the industry has to walk a narrow tightrope between keeping profitability up and quickly developing attractive medications. As patients are increasingly well informed, organized and powerful, a novel approach that some companies are looking into is patient-centrism. This means integrating patient inputs in each stage of the value chain, from drug development through commercialization to lifecycle management. We carried out 50 in-depth interviews with industry experts to find out how this new model can hold the future for the bio pharma business.